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Abstract 
Enhanced/prolonged cAMP signalling has been suggested as a suppressor of cancer proliferation. Interestingly, two 
key modulators that elevate cAMP, the  A2A receptor  (A2AR) and phosphodiesterase 10A (PDE10A), are differentially co-
expressed in various types of non-small lung cancer (NSCLC) cell-lines. Thus, finding dual-target compounds, which 
are simultaneously agonists at the  A2AR whilst also inhibiting PDE10A, could be a novel anti-proliferative approach. 
Using ligand- and structure-based modelling combined with MD simulations (which identified  Val84 displacement 
as a novel conformational descriptor of  A2AR activation), a series of known PDE10A inhibitors were shown to dock to 
the orthosteric site of the  A2AR. Subsequent in-vitro analysis confirmed that these compounds bind to the  A2AR and 
exhibit dual-activity at both the  A2AR and PDE10A. Furthermore, many of the compounds exhibited promising anti-
proliferative effects upon NSCLC cell-lines, which directly correlated with the expression of both PDE10A and the  A2AR. 
Thus, we propose a structure-based methodology, which has been validated in in-vitro binding and functional assays, 
and demonstrated a promising therapeutic value.
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Introduction
Cyclic adenosine monophosphate (cAMP) is a second 
messenger that has a major role in transduction and cell 
signaling in several pathways and biological systems [1]. 
cAMP elevation may be achieved via the activation of the 
adenylate cyclases by Gs proteins, and the inhibition of 
cAMP-degrading phosphodiesterases [2], and has been 
shown to inhibit proliferation of several cancer cell types 
such as breast cancer, colon cancer, lung cancer, glioblas-
toma etc [3–6].
Two key modulators of intracellular cAMP are the 
adenosine  A2A receptor  (A2AR) and the phosphodies-
terase 10A (PDE10A), which are often co-expressed in 
different amounts across NSCLC cell-lines. The  A2AR 
is expressed in the two histologically distinct types of 
NSCLC cell-lines, lung adenocarcinoma and squamous 
carcinoma cell-lines [7, 8]. Likewise, PDE10A is overex-
pressed in lung adenocarcinoma, and its inhibition was 
found to suppress growth [9], demonstrating a correla-
tion between the levels of overexpression and survival 
[10]. This makes these systems interesting avenues of 
investigation for relating the amount of co-expression 
of these two protein targets and their ability to elevate 
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We hypothesized that a novel approach would be to 
discover compounds, which act simultaneously as ago-
nists of the  A2AR that are also inhibitors of PDE10A. 
cAMP elevation could be achieved through the 
 A2AR-Gαs-adenylate cyclase axis, while further promoted 
by the inhibition of its breakdown via PDE10A [7, 8]. A 
multi-target approach is a departure from standard drug 
discovery practice, where one target is often the driving 
force in compound optimization. A multi-target com-
pound could, through synergistic effects, be more effec-
tive in elevating cAMP. Indeed, dual PDE inhibition and 
 A2AR activation via compound combinations exhibited 
synergy (according to isobologram analysis) in cAMP 
elevation, and was observed to inhibit proliferation in 
other cancer cell types such as multiple myeloma and 
diffuse large B-cell lymphoma [11]. The use of multitar-
get ligands have  also demonstrated beneficial effects on 
Alzheimer’s and Parkinson’s disease [12, 13]. Therefore, 
combining this approach in single dual-targeted com-
pounds at the  A2AR and PDE10A could be explored as a 
novel anti-proliferative strategy for adenocarcinoma and 
squamous carcinoma cell-lines.
For the purpose of designing PDE10A inhibitors and 
 A2AR agonists, many virtual screening protocols have 
been reported in the literature, implementing either 
ligand- or structure-based approaches Examples of 
ligand-based protocols include in silico target prediction, 
pharmacophore-based and fragment-based approaches 
and comparative molecular field analysis (CoMFA) 
[14–19]. Docking, as a structure-based approach, has 
also been employed for the design of either PDE10A 
inhibitors or  A2AR agonists [20]. In addition, molecular 
dynamics has been used extensively to investigate the 
conformational dynamics at the  A2A adenosine recep-
tor or PDE10A [20–27]. However, none of the reported 
protocols rationalizes or correctly predicts the functional 
activity of ligands against the targets of interest, in par-
ticular the  A2AR, which is addressed in this work.
Here, a novel structure-based methodology for identi-
fying ligands that activate the  A2AR while simultaneously 
inhibiting the PDE10A is devised. Given that PDE10A 
is an enzyme, compounds that target the active site 
would most likely confer inhibition. However, binding 
to the orthosteric site of the  A2AR may not guarantee the 
desired functional activity. For this reason, the structure-
based computational approach was focused on the more 
challenging goal, which involved identifying whether 
known PDE10A inhibitors are  A2AR agonists.
The focus of this approach was on the key interact-
ing residues, which are reported in the literature to dis-
criminate between agonist and antagonist activity of 
 A2AR ligands [28–31]. It is postulated that the motion of 
the residue  Val84 in Transmembrane Helix 3, upon  A2AR 
ligand binding, might discriminate between agonist and 
antagonist activity, which has not previously been studied 
by any MD approaches [19–24, 32]. Hence, the motion of 
this residue has been investigated as a conformational 
descriptor for the characterization of receptor activation 
by  A2AR ligands.
Subsequently, the selected compounds were evaluated 
pharmacologically in vitro using both binding and func-
tional assays. We then extended our studies to evaluate 
the compounds for their abilities to modulate cell prolif-
eration in lung squamous cell carcinoma and lung ade-
nocarcinoma cell-lines. Their anti-proliferative effects 
were correlated with the co-expression of the  A2AR and 
PDE10A and (increased) cellular levels of cAMP.
Results
Method for selecting triazoloquinazolines as candidates 
for dual ligand activity at  A2AR and PDE10A
Triazoloquinazolines were identified by Kalash et  al. as 
a compound series that showed the highest frequency of 
prediction as binders at the  A2AR and PDE10A by ligand- 
and structure-based approaches (Fig.  1a) [33]. For the 
purpose of finding dual-target ligands that elevate cAMP, 
the focus was on ligands that could simultaneously acti-
vate the  A2AR (agonists) and inhibit PDE10A.
From the ZINC database, six purchasable triazolo-
quinazolines (1–6) were shortlisted (compound 1–6 
Fig. 1a, see methods for details) [34], which were (Fig. 1b, 
c) previously shown to display inhibition of PDE10A 
(with a rank order of potency of 1 > 6 = 4 > 5 > 3 = 2) [34]. 
Importantly, for future reference, no significant activ-
ity of the  A2AR selective agonist CGS21680 at PDE10A 
was detected. Using a crystal structure of PDE10A (PDB 
ID: 4DDL) and ligand/protein docking, binding poses 
were found that appeared consistent (i.e. docking in 
approximately the same position) for all six compounds 
(Fig. 1d—illustration of predicted binding modes of rep-
resentative triazoloquinazolines 1 and 4). Importantly, 
this analysis highlighted that the interaction of Tyr683, 
a residue belonging to a ‘selectivity pocket’ of PDE10A, 
through a hydrogen bond with the thioether of the com-
pounds could explain their PDE10A subtype selectivity.
Following the initial shortlisting (based on PDE10A 
activity), compounds 1–6 were docked into the orthos-
teric site of the  A2AR protein crystal structure (PDB ID: 
2YDO). In this structure a relatively large displacement 
of the  Val84 residue was observed (when referenced to 
its average distance to  Leu249, a residue that is compara-
tively static in position relative to the structure as a whole 
(Additional file  1: Table  S1). The relative motion of this 
amino acid residue is essential for  A2AR activation, in 
order to avoid the steric clash that might otherwise result 
between the agonist and the receptor.
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The selection of the structure to be used as the dock-
ing model for the  A2AR was based on the  Val84-Leu249 
inter-residue distances found for the active/inactive 
forms of the  A2AR protein crystal structures reported 
in the protein data bank (PDB). Based on this criterion, 
the  A2AR crystal structure (PDB ID: 2YDO) was selected 
since it exhibited the largest inter-residue distance. It 
was hypothesized that this would allow ligand explora-
tion of a conformational space most likely to be occupied 
by  A2AR agonists when docked into the orthosteric site. 
Indeed, this enabled enrichment of  A2AR agonists over 
 A2AR antagonists and  A2AR inactives (refer to methods 
for details). This is in agreement with a previous study 
by Rodríguez et  al. [26], where the  A2AR crystal struc-
ture (PDB ID: 2YDO) displayed the highest enrichment 
factor value (EF1 %) for docked agonists over the other 
active crystal structures of the  A2AR. The 2YDO crystal 
structure enriched agonists 63.5-fold better than random 
and 2.9-fold better than antagonists (63.5 % versus 21.9 %) 
[26]. However, their docking approach failed to find any 
 A2AR agonists (which used three active structures: PDB 
IDs: 2YDO, 2YDV, and 3QAK). The authors rationalized 
this as resulting from bias of the chosen chemical librar-
ies towards  A2AR antagonists over agonists.
The evaluation of the six triazoloquinazolines 1–6 
(Fig. 1a), as promising candidates for  A2AR agonism, was 
based on their docking scores. Compounds were selected 
based on their scores below the score threshold value of 
-7.33, which was determined as the optimum selection 
criteria for agonists based on computing the Matthews 
correlation coefficient (see Methods for more details).
Compounds 1–6 were screened against PAINs (PAN 
Assay Interference Compounds) with regard to the 
recent analysis of the use of this approach by Tropsha 
using FAFDrug3 [35], and none of the compounds exhib-
ited any potential PAINs liability.
Analysis of the molecular docking studies 
of the representative triazoloquinazolines 1–4 shortlisted 
for experimental validation
Docking studies predicted consistent molecular interac-
tions for the triazoloquinazolines, similar to those of the 
co-crystallized ligand bound to the  A2AR protein crys-
tal structure (PDB ID: 2YDO). Representative and dis-
tinct binding modes are illustrated in Fig. 2. Compounds 
1–3, were predicted to be selective  A2AR ligands, which 
was attributed to interactions with  His250 [36, 37]. This 
residue is located in the core region of the receptor and 
part of a sub-pocket formed by  Leu85,  Met177,  Trp246 
and  Leu249. Despite the fact that it is conserved among 
the  A1R and the  A2AR subtypes (as suggested by a recent 
study [38], due to the high conservation of amino acid 
residues in the adenosine receptor subtypes), subtype 
selectivity might not be attributed to the receptor-spe-
cific amino acid residues, but rather to conformational 
differences. Also, given that mutation experiments have 
failed so far to highlight any receptor-specific amino acid 
residues responsible for subtype selectivity, this would 
Fig. 1 The Structures of the identified PDE10A inhibitors with the potential to bind to the  A2AR, and their pharmacology at PDE10A. a Virtual 
screening protocol. b Chemical structures for the six compounds identified in the in silico screen, literature references, compound IDs (used here) 
and  pIC50 for PDE10A inhibition. c Concentration-response curves generated for 1–6 and CGS21680 at PDE10A. Data is the mean of six individual 
replicates ± SEM. d Representative binding modes proposed for the triazoloquinazolines 1 and 4 docked to the PDE10A crystal structure (PDB ID: 
4DDL). Yellow spheres indicate lipophilic contacts. Aromatic interactions are illustrated by purple disks and hydrogen bond acceptors are shown 
as red arrows.  Tyr683 is part of the “selectivity pocket” of PDE10A [33], and its interaction through a hydrogen bond with the thioether of both 
compounds could explain their subtype selectivity
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add weight to the suggested hypothesis [37, 39]. Hence, 
the selectivity of  A2AR agonists could be attributed to 
the conformational preferences of the  His250 amino acid 
residue that contributes to shaping the orthosteric site 
to favor their selectivity [38]. Indeed, the interaction 
with this residue is only observed for the selective  A2AR 
co-crystallized agonists, CGS21680 (PDB ID: 4UHR) 
and UK432097 (PDB ID: 3QAK) but not for the non-
selective co-crystallized agonists NECA (PDB ID: 2YDV) 
and adenosine (PDB ID: 2YDO). These results appear to 
confirm that interactions with  His250 serve to improve 
binding to the lipophilic sub-pocket which suggests this 
is a driver for  A2AR sub-type selectivity. In terms of func-
tional activity however, the occurrence of this interaction 
cannot discriminate between agonists and antagonists 
[37, 39].
Compound 1 hydrogen bonds via the nitrogen of the 
quinazoline ring with  Asn253, and via the imidazo ring 
with  Glu169. The triazole ring is π-stacked with  Phe168, 
and the phenyl group in quinazoline is π-stacked with 
 His250 (Fig.  2). Compound 4 shows π-stacking with 
 Phe168. The selective  A2AR agonist, compound 1  is pre-
dicted to bind deeper within the receptor core and to 
directly interact with  His250 and  Asn253, which is con-
sistent with the experimentally observed interactions 
between the co-crystallized ligands and the active  A2AR 
crystal structures (PDB IDs: 4UG2, 4UHR, 3QAK, 
2YDO and 2YDV). The compounds were not predicted 
to display all the interactions exhibited by the agonist 
co-crystallized ligands [28–30], in particular the  Thr88 
and  Ser277 interactions, which are also characteristic of 
the ZM241385 antagonist [27]. Hence, these interaction 
types are not characteristic of agonist activity. However, 
it has been reported in the literature that mutating these 
residues has a stronger influence on agonist activity than 
upon the antagonist activity of the  A2AR ligands, but not 
on the binding to the  A2AR [37–39]. As for the co-crys-
tallized  A2AR antagonists (PDB ID: 5IU4 3UZA, 5K2A, 
4EIY, 3EML, 5NM2, 5JTB, 5UVI, and 5UIG), these only 
show interactions with  Phe168,  Asn253, and  Glu169 resi-
dues. Therefore, the type of predicted interaction is not 
indicative of receptor activation by the triazoloquinazo-
lines. However, the docking model used enriched  A2AR 
agonists (exhibited higher docking score distribution) 
over  A2AR antagonists and  A2AR inactives (compounds 
that do not bind to the  A2AR). This suggested an inves-
tigation (using molecular dynamics) into whether the 
 His250 movement would differ between selective versus 
non-selective  A2AR agonist binding (discussed in the sup-
porting information) and also to investigate whether the 
motion of  Val84 would vary upon agonist and antagonist 
binding. This could allow discrimination between these 
different classes of compounds.
Fig. 2 Docking studies predicted molecular interactions similar to those observed for triazoloquinazolines in the  A2AR protein crystal structure (PDB 
ID: 2YDO). Distinct binding modes are shown for compounds 1 and 4. a Compound 1 hydrogen bonds via the nitrogen of the quinazoline ring with 
 Asn253 and via the imidazo ring with  Glu169. The triazole ring is π-stacked with  Phe168, and the phenyl group in quinazoline is π-stacked with  His250 
b Compound 4 shows π-stacking with  Phe168. It can be seen that the  A2AR selective agonist 1 is predicted to bind deeper within the binding site 
and interacts with  His250 and  Asn253, which is consistent with binding modes observed in crystallographic data (PDB IDs: 4UG2, 4UHR, 3QAK, 2YDO 
and 2YDV). The essential role of  His250 in shaping the binding site was supported by MD simulation. Yellow spheres indicate lipophilic contacts, red 
arrows show hydrogen bond acceptors and purple disks indicate aromatic interactions
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Analysis of MD Simulations reveals that a shift in  Val84 
is one requirement for receptor activation by  A2AR ligands
The analysis of the active and inactive forms of the avail-
able  A2AR crystal structures is in accordance with reports 
in the literature, which mention that  Val84 in TM3 has 
to move by approximately 2 Å upon agonist binding to 
avoid a steric clash between the ligand and the receptor 
[29–31]. This gave rise to the hypothesis that the motion 
of this residue might discriminate between agonist and 
antagonist binding (Fig. 3a).
MD simulations (100 ns) were performed for the co-
crystallized structures (PDB IDs: 5IU4 and 2YDO), which 
exhibited the largest differences observed in the distance 
between the α-carbons of  Val84 in TM3, and  Leu249, a 
relatively fixed residue in TM6 (12.96 Å and 14.53 Å, see 
methods for details). The same MD analysis was carried 
out for the apo structure of the  A2AR (PDB ID: 5IU4), the 
docked triazoloquinazolines 1, 4 and 5 with the highest 
predicted affinities, compound 6 (with lowest predicted 
affinity), CHEMBL3799351 (a potent antagonist), and 
CGS21680 (the selective and potent  A2AR agonist). All 
these compounds were docked into the orthosteric site 
of the inactive form of the  A2AR protein crystal struc-
ture (PDB ID: 5IU4), Additional file 1: Figure S4. For the 
first 50 ns the structures were considered to be relaxing 
to an annealed state. For the subsequent 50 ns the agonist 
bound structures showed an increase of the Cα distances 
between  Val84 and  Leu249, with an increased distance 
equivalent to the active protein crystal structure (PDB 
ID: 2YDO). Compound 6, the apo structure, and the 
antagonist bound structures did not exhibit this increase 
in Cα distances and instead showed a slight decrease in 
the Cα distances for the antagonist bound structures in 
comparison to the apo structure and compound 6.
To gain further insights from the change in the Cα dis-
tances between  Val84 and  Leu249 for the agonist bound 
structures (which are the systems of interest in this 
study), longer simulations of 500 ns were carried for com-
pounds 1, 5, and CGS21680, in addition to the active and 
inactive cocrystal structures (PDB IDs: 2YDO and 5IU4). 
The simulations were run in duplicate.
The same trends were observed in the longer simula-
tions. Over the first 50 ns the structures were annealing, 
and for the rest of the simulation (the last 450 ns) com-
pounds 1, 5 and CGS21680 increased their Cα distances 
between  Val84 and approaching the distance observed for 
the active protein crystal structure (PDB ID: 2YDO), as 
shown in Fig.  3b, c. Hence, the increase in the distance 
between  Val84 and  Leu249 residues observed upon  A2AR 
agonist binding appears to serve as a useful conforma-
tional descriptor for receptor activation by  A2AR ligands.
Characterisation of triazoloquinazolines affinity constant 
at adenosine  A2AR
We sought to  validate the docking studies by quantify-
ing the affinity of each compound at the  A2AR using a 
Fig. 3 a The aligned and superimposed active (PDB ID: 2YDO in blue) and inactive conformations (PDB ID: 5IU4 in grey) of the  A2AR protein crystal 
structures. The  Val84-Leu249 Cα distances were measured for the active and inactive conformations and were 14.53 Å and 12.96 Å respectively 
b The moving average trend-lines (bin-size of 20 frames) are for the  Val84-Leu249 Cα distances of the apo structure (PDB ID: 5IU4) and the docked 
and the co-crystallized structures (PDB ID: 5IU4 and 2YDO use the same color code as 3A) of the  A2AR over a simulation of 100 ns. Compounds 1, 
5 and CGS21680 are docked into the inactive form of the  A2AR protein crystal structure (PDB ID: 5IU4). The variations in the computed distances 
for compounds 1, 5 and CGS21680 were similar - all increased their average distances over time, moving closer to the average distance observed 
in the active protein crystal structure (PDB ID: 2YDO). c Violin plots for distance distributions (same color code of Fig. 3b) for the last 450 ns of the 
simulations shows higher  Val84-Leu249 distances for the agonist bound to the  A2AR in comparison to the antagonist bound to the  A2AR. Hence, 
the increase in the  Val84-Leu249 inter-residue distance upon  A2AR agonist binding serves as a promising conformational descriptor for receptor 
activation by  A2AR ligands. A statistical analysis was performed on the distance distributions for the last 450 ns using a Mann-Whitney test and a 
Kolmogorov-Smirnov test. The differences in medians of the distance distributions for each of the agonists versus the antagonist were significant at 
a p value < 0.05, and the p value for the Kolmogorov-Smirnov test was < 2.2 ×  10− 16
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NanoBRET binding assay. In this experiment, we used 
N-terminally tagged  A2AR with Nanoluciferase (Nluc) 
that will emit bioluminescence in close proximity with 
the fluorescent probe, CA200645, in the presence of Nluc 
substrate. Firstly, we determine the affinity constant of 
CA200645 in our expression system. CA200645 has been 
extensively used to characterise ligand binding properties 
at adenosine receptor subtypes [40–42]. Using HEK293 
cells we determined the disassociation constant  (KD) of 
CA200645 at the Nluc-A2AR to be 65 nM (Fig.  4a). We 
next extended our studies to use a classical competition 
binding assay ([43, 44]) where non-fluorescent ligands 
compete for binding at the Nluc-A2AR with CA200645. 
Using this approach, we determined the pKi for NECA as 
6.36 ± 0.09 and CGS21680 as 6.39 ± 0.04 while isoprena-
line (a non-selective agonist of β-adrenoceptors) failed 
to displace CA200645 (Fig. 4b). We next determined the 
rank order of affinities for the  six triazoloquinazolines 
compounds at the  A2AR to be: cmpd 4 > cmpd 2 > cmpd 
6 > cmpd 1 = cmpd 3 > cmpd 5 (note: under condition 
tested, cmpd 5 was unable to fully displace CA200645) 
(Fig. 4c, d).
Identifying AR subtype selectivity of triazoloquinazolines
Identification  of AR subtype selectivity of triazolo-
quinazolines was performed using previously character-
ised yeast strains expressing human  A1R,  A2AR or  A2BR 
[45]. The  A3R cannot be functionally expressed in yeast 




































































































Fig. 4 Characterisation of ligands targeting  A2AR/PDE10A using a NanoBRET-based ligand binding assay. a Kinetic binding curve of CA200645 at 
Nluc-A2AR expressed HEK293T cells. After 19 minutes association with 40 nM CA200645, CGS21680 was injected to give a final concentration of 
10 µM in order to displace the fluorescent probe. The curve was fit into “association then dissociation” model built in Prism 8.4.3. b Competition 
of CA200645 (300 nM) by reference compounds including CGS21680, NECA, and isoprenaline at equilibrium. c Competitive binding curves of 
triazoloquinazolines in correspond to of 300 nM CA200645. Both curves (panel B and C) were fitted using the “one-site Ki” equation where  KD and 
concentration of hot ligand were set to 65 nM and 300 nM, respectively. Data points are the mean ± SEM from 3–27 repeats performed in duplicate. 
(D) The summary of binding affinities  (pKi) of tested ligands.  pKi values were calculated from inhibition of CA200645 binding at equilibrium to 
Nluc-A2AR-expressed HEK293T cells. 
# Cmpd 5 did not fully displace binding of CA200645 under condition tested. Statistical significance (*p < 0.05; 
**p < 0.01; ***p < 0.001; ****p < 0.0001) compared to CGS21680 was determined by one-way ANOVA with Dunnett’s post-test 
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(Knight et al., 2016), therefore we utilised CHO-K1 cells 
stably expressing  A3R (CHO-K1-A3R). Testing the com-
pounds in these systems identified compounds 1, 2, 3, 
4, 5 to be  A2AR agonists, whilst compounds 1, 2, 3 are 
 A2AR-selective (Fig.  5, Additional file  1: Table  S2).  It is 
interesting to note that compound 6 was able to bind to 
the  A2AR but given that in the yeast based assay it failed 
to elicit a functional response, we suggest it maybe an 
 A2AR antagonist.
To further verify the efficacy of compounds against the 
 A2AR, we assayed their ability to stimulate cAMP produc-
tion using CHO-K1 cells stably expressing human  A2AR 
(CHO-K1-A2AR). All compounds tested were observed 
to be partial agonists, relative to CGS21680, with a rank 
order of potency of CGS21680 > 5 = 4 > 1 = 3 > 6 > 2 
(Fig.  6; Table  1). Antagonism with ZM241385 displayed 
non-classical antagonism, which is presumed to be due 
to the dual effects upon endogenous PDE10A (Addi-
tional file 1: Figure S5). For compound 6, treatment with 
ZM241385 solely reduced  Emax and basal levels, with no 
effect on the response range (Fig. 6; Table 1). ZM241385 
has been suggested to be an inverse agonist at the  A2AR 
potentially explaining these effects [30]. Importantly, all 
compounds were able to stimulate cAMP production 
in the absence of the  A2AR, or in the presence of 1 µM 
ZM241385, presumably from inhibition of PDE10A. 
Thus, we observe a significant increase in efficacy of 
compounds 1–5 via the additional action upon the  A2AR 
(Fig. 6; Table 1), which could be attributed to an additive 
action in elevating intracellular cAMP levels.
Dual PDE 10A inhibition and  A2AR agonism is anti‐
proliferative in CHO‑K1‑A2AR cells
Both CHO-K1 and CHO-K1-A2AR cells displayed 
concentration-dependent inhibition of cell prolifera-
tion when stimulated with forskolin (Additional file  1: 
Figure S6, Table  S3), confirming the anti-proliferative 
effects of cAMP. However, sole activation of the  A2AR, 
via CGS21680 stimulation, had no anti-proliferative 
effects upon either cell type (Additional file 1: Figure S6, 
Table S3). In contrast stimulation with compound 1 dis-
played  A2AR-dependent inhibition of cell growth. Com-
pounds 3–5 show anti-proliferative effects in CHO-K1 
cells, which increased in terms of both potency and effi-
cacy when the  A2AR was expressed (Additional file  1: 
Figure S6, Table  S3). Compound 2 appeared to be anti-
proliferative regardless of the cell type tested whereas 
Compound 6 displayed little anti-proliferative action 
implying that that sole inhibition of PDE 10A has little 
effect upon the proliferation of CHO-K1 cells (Additional 
file 1: Figure S6, Table S3).
Dual PDE 10A inhibition and  A2AR agonism 
is anti‑proliferative in Lung carcinoma cells
Having established that the compounds 1–5 appear to 
have dual activity in CHO-KI cells where the  A2AR was 
over expressed we then extended our studies to a series of 
lung carcinoma cells: two lung squamous cell carcinomas 
(LUSC): LK-2 and H520, and two lung adenocarcinoma 
cells (LUAC): H1563 and H1792, which express differ-
ing levels of the four adenosine receptor subtypes and 
PDE10A (Fig. 7a). Using these cell lines, we investigated 
the effects of compounds of our dual-target compounds 
upon cAMP production and proliferation (Fig. 7). Note, 
compound 2 was not analysed for cAMP production in 
this study due to apparent off-target toxic effects upon 
CHO-K1 cell proliferation—a feature also noted in all 
four lung carcinoma cell lines.
LK-2 cells express the  A1R,  A2BR and very low levels 
of PDE10A, but lacked expression of the  A2AR (Fig. 7a). 
In these cells compound 3 and to a lesser extent com-
pound 4 were able to stimulate cAMP production 
(Fig.  7a, Additional file  1: Table  S4). However, only 
forskolin and compound 3 (Fig.  7a, Additional file  1: 
Table S5) displayed any anti-proliferative actions. Thus, 
in the absence of significant PDE10A or  A2AR expres-
sion, compound 1 and 5 displayed little activity. Com-
pound 4  is an agonist for the  A2BR so presumably this 
explains its ability to stimulate cAMP production. The 
action of compound 3 was somewhat of a surprise and 
may suggest it has additional activities beyond  A2AR 
and PDE10A. By means of a comparison, H520 cells 
express all four ARs, but no PDE 10A. In these cells, we 
were able to observe stimulation of cAMP accumulation 
when exposed to all compounds except for compound 
6, which displayed low potency and efficacy (Fig.  7, 
(See figure on next page.)
Fig. 5 Dose-response curves for NECA, CGS21680 and compounds 1–6 in either the  A1R and GPA1/Gαi1/2,  A2AR and GPA1/ Gαs, or the  A2BR (with 
GPA1/Gαs expressed in yeast strains). The efficacy of the compounds (1–6) was measured against  A3R in CHO-K1-A3R cells. Reporter gene activity 
in yeast was determined using β-galactosidase assays, after 16-hours stimulation with either: NECA (a), CGS21680 (b) compound 1 (c), compound 
2 (d), compound 3 (e), compound 4 (f), compound 5 (g), compound 6 (h), whereas cAMP inhibition was determined when in CHO-K1-A3R cells 
which were co-stimulated with each of the compounds 1–6 and 1 µM Forskolin. In general, the triazoloquinazolines 1–5 exhibited agonistic activity 
against the adenosine receptor sub-types, with compounds 1–3 being selective  A2AR agonists. The data is represented as either percentage of 
the response obtained upon stimulating each receptor  (A1R,  A2AR, or  A2BR) with NECA stimulation, or as a percentage response relative to 100 µM 
Forskolin simulation in the  A3R ± SEM of 4–6 individual replicates
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Additional file  1: Table  S4). The increase in activity of 
the compounds was also apparent for proliferation 
assays, where compounds 1, 3–5 all displayed anti-
proliferative activity with higher affinity and efficacy 
than that observed in the LK-2 cells (Fig. 7, Additional 
file  1: Table  S5). This data highlights the potential of 
the compounds to prevent proliferation when the  A2AR 
is expressed. Likewise, in H1792 cells we observe the 
expression of all four ARs and an increase in PDE10A 
expression, relative to H520 cells (Fig.  7). Again, we 
observed the ability of all compounds to elevate cAMP 
levels, whilst compounds 1, 3, 4 and 5 act in an anti-
proliferative manner (Fig. 7, Additional file 1: Tables S4, 
S5). The same was also apparent for H1563 cells, which 
in contrast to H1792 cells express much higher levels 
of PDE10A (Fig. 7, Additional file 1: Tables S4, S5). By 
comparing the observed potencies for proliferation and 
cAMP assays, across all cell types, for all anti-prolif-
erative compounds, a strong correlation was observed 
(Fig. 7B, r = 0.80, 95 % CI; 0.85–0.91). This suggests that 
through improving efficacy in terms of cAMP produc-
tion, an increased efficacy can also be achieved in terms 
of proliferation inhibition.
Finally, to provide convenient means by which to com-
pare the anti-proliferative activities of the compounds 
tested in this study, we multiplied the potency term 
(affinity) for the compounds by their efficacy (span of 
antiproliferation)—generating a ‘proliferation factor’ 
term as described previously [46]. Using this analysis, 
we can observe that compounds 1, 3, 4 and 5, all display 
improved efficacy when both PDE10A and  A2AR are pre-
sent in the cells (Fig. 7). In contrast, compound 6 displays 
no anti-proliferative activity in any cell type tested whilst 
CGS21680 is only anti-proliferative in H1563 cells (Fig. 7, 
Additional file  1: Table  S5), suggesting these are more 
sensitive to proliferation inhibition. In contrast, forsko-
lin displays near equal activity in all cell types tested. As 
described earlier, compound 3 displayed activity in all 
four NSCLC cell lines suggesting it may display off target 
effects. Significantly, it is worth highlighting that com-
pound 4 displayed higher efficacy when the  A2BR was 
most abundantly expressed in cells. This directly corelates 
with it being non-selective at the different AR subtypes 
and suggests it may be a pan-AR/PDE10A compound.
Conclusions
In this work, a novel structure-based approach has been 
successful in identifying triazoloquinazolines as the first 
dual ligands that activate the  A2AR and inhibit PDE10A 
simultaneously. Docking of the triazoloquinazolines 1–6, 
which are known PDE10A inhibitors, was performed 
on the orthosteric site of the  A2AR (PDB ID: 2YDO). It 
is demonstrated experimentally using a BRET-based 
ligand-binding assay that these ligands indeed bind to 
the  A2AR. The rank order of affinity for the six triazolo-
quinazolines at the  A2AR was found to be: cmpd 4 > cmpd 
2 > cmpd 6 > cmpd 1 = cmpd 3 > cmpd 5.
Functional analysis in yeast-screening assay and in 
mammalian cells demonstrated that compounds 1–5 
were  A2AR agonists and revealed that compounds 1–3 are 
selective for the  A2AR. It is suggested that the observed 
 A2AR sub-type selectivity for 1–3  is attributed to their 
predicted interactions with the  His250 residue, which is 
an interaction present only in the selective co-crystal-
lized  A2AR agonists, such as CGS21680 and UK432097. 
It was further demonstrated by MD simulation analysis 
that this residue undergoes conformational changes only 
when selective  A2AR agonists are bound and not when 
non-selective agonists bind to  A2AR. This could contrib-
ute to shaping the orthosteric site to favor selectivity of 
 A2AR agonists. Moreover, MD analysis highlighted the 
motion of  Val84 in TM3 as an essential requirement for 
 A2AR activation.
Compounds 1 and 3–5 exhibited promising concen-
tration-dependent anti-proliferative effects in lung squa-
mous cell carcinoma cells and lung adenocarcinoma 
cells, which correlated with co-expression of  A2AR and 
PDE10A and increased cellular levels of cAMP. Com-
pound 1 (as a selective  A2AR agonist and a PDE10A 
inhibitor) exhibited increased potency for both cAMP 
accumulation and anti-proliferative actions, which 
increased in tandem with the combined target expression 
 (A2AR and PDE10A) across the NSCLC cell lines, from 
LK-2-H520-H1792-H1563. Hence, the structure-based 
approach proposed in this work has been successfully 
validated using binding and functional assays, and it pro-
vides a template for generating  A2AR agonists as part of a 
dual-target design objective.
Fig. 6 CGS21680 and compounds 1–6 elevated cAMP in  A2AR stably expressed in CHO-K1 cells, which were antagonized by ZM241385.  A2AR stably 
expressed in CHO-K1 cells (CHO-K1-A2AR) were stimulated for 30 minutes with: CGS21680 (a), compound 1 (b), compound 2 (c), compound 3 (d), 
compound 4 (e), compound 5 (f), or compound 6 (g), after which the cAMP levels were determined. Subsequently compounds were antagonized 
with either 100 pM, 10 nM or 1 µM ZM241385, which decreased the cAMP levels to the same level of CHO-K1 cells (no  A2AR stably expressed). Data 
represented are relative to the response of CGS21680, ± SEM of 4–9 individual replicates
(See figure on next page.)
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Methods
Design approach for the discovery of dual ligands 
at the  A2AR and PDE10A
Triazoloquinazolines were shortlisted as candidates of 
dual ligands at the  A2AR and PDE10A since this chemi-
cal series were predicted to show activity based on 
ligand- and structure- based techniques [33]. The focus 
was on discovering compounds that elicited an eleva-
tion of cAMP by the activity of ligands having dual 
effects, simultaneously agonists at  A2AR and inhibitors of 
PDE10A.
From the ZINC database, eleven purchasable tria-
zoloquinazolines that were experimentally determined 
as PDE10A inhibitors were identified using a search for 
the triazoloquinazoline substructure with the following 
criteria: Uniprot ID: Q9Y233 and  IC50 < 10 µM. Identi-
fied triazoloquinazolines had the following ZINC IDs: 
3,154,141, 3,141,002, 6,206,233, 9,937,921, 9,939,949, 
2,968,902, 14,728,559, 424,907, 13,229,753, 44,924,158, 
and 8,747,709. These were downloaded for subsequent 
docking into the orthosteric site of the  A2AR protein crys-
tal structure.
Selection of the  A2AR protein crystal structure 
for shortlisting triazoloquinazoline candidates as  A2AR 
agonists
All the active forms of the  A2AR protein crystal struc-
ture with the following PDB IDs (4UG2, 4UHR, 3QAK, 
2YDO, and 2YDV) and the inactive forms with the fol-
lowing PDB IDs (5IU4, 3UZA, 5K2A, 4EIY, 3EML, 
5NM2, 5JTB, 5UVI, and 5UIG) were downloaded into 
MOE [47]. It has been reported in the literature that  Val84 
in TM3, which is located in the orthosteric site, has to 
shift its position upon agonist binding owing to a steric 
clash with the ligand, which may contribute to the 2 Å 
shift observed in H3 [29–31]. To evaluate the change in 
the interaction upon agonist binding, the distance was 
calculated from a single amino acid residue to  Val84. This 
gave a frame of reference to compare structures. The 
‘fixed’ amino acid residue selected was  Leu249 in TM6. 
This was achieved by aligning all the active and inactive 
forms of the  A2AR protein crystal structures (using the 
sequence editor > alignment > align/superimpose option). 
Then, the mean RMSD displacement from the mean of 
all the aligned structures was calculated for  Leu249, which 
turned out to be low (0.40 Å) confirming that it is reason-
ably static in its relative position.
For each PDB ID of the active and inactive forms of 
the  A2AR crystal structures, the distance between the 
α-carbons of  Val84 in TM3 and  Leu249 in TM6 was meas-
ured in MOE using the measure > distances option. 
Additional file 1: Table S1 lists all the  Val84-Leu249 inter-
residue distance values. The inter-residue distances of 
the active forms ranged from 14.30 to 14.53 Å, and for 
the inactive forms they ranged from 12.96 to 13.36 Å. The 
largest displacement of the  Val84 residue was measured 
for the active form in PDB ID: 2YDO, and the distance 
was equal to 14.53 Å. This can be compared to the inac-
tive form of the  A2AR protein crystal structure (PDB ID: 
5IU4), which had the minimum distance (12.96 Å). Given 
that  Val84 displayed the highest displacement from the 
 Leu249 residue in the protein crystal structure with the 
PDB ID: 2YDO, it was selected as the best candidate for 
shortlisting candidates of  A2AR agonists.
Ligand preparation
39 potent agonists and 38 potent antagonists of the  A2AR 
(Uniprot ID: P29274) with  EC50 and  IC50 values less 
than 1 µM and confidence scores equal to 9 were manu-
ally extracted from ChEMBL. 133  A2AR inactives were 
Table 1 Potency  (pEC50) and  range of  responses for  cAMP production upon  CGS21680 and  triazoloquinazoline 
stimulated cAMP accumulation in CHO-K1-A2AR and CHO-K1 cells
Data ± SEM of n individual replicates. aNegative logarithm of agonist concentration producing half-maximal response. bPercentage range of response observed 
upon agonist stimulation, relative to that obtained with CGS21680 stimulation in each cell type. cChange in  pEC50 between CHO-K1 and CHO-K1-A2AR cells (Δ 
 pEC50 =  pEC50(CHO-K1-A2AR) -  pEC50(CHO-K1)). dChange in range between CHO-K1 and CHO-K1-A2AR cells (Δ Range = Range (CHO-K1-A2AR) - Range (CHO-K1)). ND 
Not determined, full dose-response curve not feasible. Statistical difference, between CHO-K1-A2AR cells and CHO-K1 cells, was calculated using pair-wise t-tests, for 
each agonist (*p < 0.05, **p < 0.01, ***p < 0.001)
CHO‑K1‑A2AR CHO‑K1 CHO‑K1‑A2AR vs. CHO‑K1
pEC50
a Rangeb n pEC50
a Rangeb n Δ  pEC50
c Δ  Ranged
CGS21680 8.78 ± 0.2 86.33 ± 7.2 9 ND ND 4 – –
Cmpd 1 7.32 ± 0.2 61.14 ± 5.2*** 8 6.49 ± 0.3 20.19 ± 2.7 4 0.83 ± 0.5 40.95 ± 7.80
Cmpd 2 6.29 ± 0.5** 30.50 ± 8.1 6 4.85 ± 0.2 39.46 ± 3.9 4 1.44 ± 0.6 − 8.96 ± 10.6
Cmpd 3 7.26 ± 0.3** 28.95 ± 6.3 6 5.90 ± 0.3 18.32 ± 2.3 4 1.21 ± 0.5 10.63 ± 8.70
Cmpd 4 7.55 ± 0.2 37.71 ± 2.9** 5 6.62 ± 0.2 18.75 ± 1.7 4 0.93 ± 0.6 18.96 ± 3.60
Cmpd 5 7.70 ± 0.4** 27.42 ± 4.4 6 6.30 ± 0.2 19.49 ± 1.7 4 1.28 ± 2.4 7.93 ± 6.1
Cmpd 6 6.52 ± 0.4 33.87 ± 5.3 6 6.35 ± 0.3 31.42 ± 4.6 4 0.17 ± 0.8 2.45 ± 9.9
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extracted from PubChem using SQL and the eleven pur-
chasable triazoloquinazolines were selected from the 
ZINC database. The entire set of ligands were prepared 
for docking into the orthosteric site of the  A2AR protein 
crystal structure, with LigPrep 2.5 [48]. using the default 
settings and the Epik option, which introduces energy 
penalties associated with ionization and tautomerization 
[49].
Receptor preparation
Docking with Glide [50] was performed against the 
human  A2AR protein crystal structure (PDB IDs: 2YDO 
and 5IU4). The protein structures were prepared using 
the Protein Preparation Wizard of Maestro 9.3 [51], fol-
lowing the default protocol, which accounts for energy 
refinement, hydrogen addition, pKa assignment, side-
chain rotational isomer refinement, and addition of 
missing residues and side-chains with Prime 3.1 [52]. 
Resolved water molecules were discarded, and the struc-
ture was centered using the co-crystallized ligand as the 
center of the receptor grid generated for each protein 
structure. The co-crystal structures of  A2AR with Aden-
osine (PDB ID: 2YDO) and with ZM241385 (PDB ID: 
5IU4) were selected as target structures.
Compound 1 Compound 3
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Fig. 7 Lung squamous cell carcinoma and adenocarcinoma cells display increasing sensitivity to compounds 1, 3–5 in terms of proliferation, 
dependent upon combined  A2AR and PDE10A expression. Lung squamous cell carcinoma cells (LK-2 and H520) and lung adenocarcinoma cells 
(H1792 and H1563 were subjected to semi-quantitative RT-PCR analysis to determine expression of the  A1R,  A2AR,  A2BR,  A3R and PDE 10A, data 
represented relative to GAPDH expression, ± SEM of 3 individual replicates. Further, each cell line was stimulated with CGS21680 or compounds 
1, 3–6 for 30 minutes and cAMP levels determined. Data represented relative to the response obtained upon stimulation with 100 µM Forskolin, 
± SEM of 4–8 individual replicates. Additionally, all cells were stimulated with CGS21680, or 1, 3–6 for 72 hours and cell number determined using 
CCK-8. Data represented as a percentage of the cell number present after treatment with 1 % DMSO, ± SEM of 4–8 replicates. (B) Correlation plot 
for  pEC50 of each compounds ability to stimulate cAMP production vs. its  pIC50 for inhibiting proliferation. Data represented ± SEM. (C) Proliferation 
factor (pIC50 x span anti-proliferative  Additional file 1: Table S5) calculated for 1, 3–6, CGS21680s and forskolin at LK-2, H520, H1792 and H1563 cells. 
Bars represent the mean  Imax ± SEM, whilst individual data points are shown as a scatter plot.
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Enrichment of agonists by the  A2AR docking model (PDB 
ID: 2YDO)
In an attempt to validate the  A2AR docking model, the 
set of prepared  A2AR agonists, antagonists and inactives 
were docked using Glide against the prepared protein 
structure.
The Glide docking parameters used were extra preci-
sion (XP) and flexible ligand sampling, which obtained 
the best separation for the medians of docking score 
distributions for agonists versus antagonists and ago-
nists versus inactives of the  A2AR. This implies that this 
docking model enriches the agonists. Additional file  1: 
Figure S7 shows the separation of the medians for the 
 A2AR docking model: (A) −  11.24 (agonists) (B) −  7.88 
(antagonists) and (C) − 6.74 (inactives). Statistical analy-
sis was performed with R using a Mann-Whitney test on 
the agonist and antagonist docking score distributions, as 
well as agonist and inactive docking score distributions. 
The differences in medians were significant at a p value of 
less than 0.05 [33].
Cut‐off generation for compound selection as candidates 
of  A2AR agonists from the docking model
The Matthews correlation coefficient (MCC), which takes 
into account true and false positives (agonists) and nega-
tives (antagonists), was computed (using a Python script 
[33]) for the docking scores of the agonists and antago-
nists against the  A2AR docking model. A search was 
performed for a docking score threshold that gave the 
highest MCC in order to shortlist promising candidates 
of  A2AR agonists, which displayed docking scores that are 
lower than the score with the highest MCC, and this gave 
a threshold of -7.33 for the  A2AR docking model.
Docking
The eleven purchasable triazoloquinazolines, which were 
prepared with LigPrep, were docked against the  A2AR 
protein crystal structure (PDB ID: 2YDO). The Glide 
docking parameters used were extra precision (XP) and 
flexible ligand sampling. The parameters were deduced 
from docking experiments using known actives and 
inactives against the protein-docking model. The  A2AR 
protein is fairly rigid as assessed by thermal stability (B 
factor) in Glide [53]. Six triazoloquinazolines (1–6) dis-
played docking scores that are lower than − 7.33, which 
was the docking score with the highest MCC for the 
known agonists and antagonists. Their chemical struc-
tures are depicted in Fig.  1. Additionally compounds 
1, 4 and 5 (with the highest predicted affinities and the 
most potent agonists identified), compound 6 (which did 
not exhibit any agonist activity), CHEMBL3799351 (an 
antagonist with an  IC50 = 4.35 nM and confidence score 
equal to 9) and CGS21680 (the selective and potent  A2AR 
agonist) and adenosine (a non-selective adenosine recep-
tor agonist), were docked into the inactive form of the 
 A2AR protein crystal structure (PDB ID: 5IU4) for MD 
simulation and analysis. The six triazoloquinazolines (1–
6) were then shortlisted for validation as  A2AR agonists in 
relevant biochemical assays.
MD simulations
Based on a structural analysis of the available  A2AR 
crystal structures, the distance between the α-carbons 
of  Val84 in TM3 and  Leu249 in TM6 was selected for 
investigation as a conformational descriptor for recep-
tor activation. The two  A2AR co-crystallized structures 
(PDB IDs: 5IU4 and 2YDO), which exhibited the larg-
est difference in α-carbon distances between  Val84 in 
TM3 and  Leu249 in TM6 (12.96 Å versus 14.53 Å respec-
tively), were selected for molecular dynamics simula-
tion. Subsequently, compounds 1, 4, 5, and 6 that were 
docked into the orthosteric site of the inactive form of 
the  A2AR protein crystal structure (PDB ID: 5IU4) were 
subjected to a 100 ns MD simulation protocol. Like-
wise, CHEMBL3799351, CGS21680 and adenosine were 
docked into the orthosteric site of the inactive form of 
the  A2AR protein crystal (PDB ID: 5IU4) to obtain simu-
lations of control compounds. The apo structure (PDB 
ID: 5UI4) was also selected for the same analysis.
The starting structures were prepared using Maestro 
9.3 following the default procedure for protein prepara-
tion. The protocol adds missing residues and sidechain 
information with Prime 3.1 [52], and uses the “Cap ter-
mini” option that adds the coordinates to the residue. 
Next, “Analyze network” in the interactive hydrogen 
bond optimizer was used to check on the assignments of 
hydrogen orientations in the hydrogen bonding network. 
They were subsequently optimized. All MD simulations 
described in this study were performed using Desmond 
3.2, available in the Schrödinger software package Release 
2016-3 with the default force field OPLS3 [54]. An 
orthorhombic box was used to build the model systems 
with periodic boundary conditions in an isothermal–iso-
baric ensemble with a constant number of particles (NPT 
ensemble). The system temperature was kept at 300 K, 
and the pressure was kept at atmospheric pressure. The 
definition of transmembrane regions was taken from the 
OPM database [55]. The receptor structures were embed-
ded in a pre-equilibrated palmitoyloleoyl-phosphatidyl-
choline membrane (bilayer) and solvated with simple 
point charge water and 0.15 M NaCl. All other parame-
ters were set to default values (refer to Additional file 1: 
Table S6 in supporting information). The 100 ns simula-
tions were carried out with Desmond 3.2 via command 
line on the computer cluster CALCULON (University 
of Cambridge) by using 20 central processing units. For 
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each compound, the simulations were performed twice, 
and the trajectories obtained were analyzed with the 
software VMD. Then plots were obtained for the RMSD 
values of  His250 in TM6, and the α-carbons distances 
between  Val84 in TM3 and  Leu249 in TM6 for the simu-
lated systems over 100 ns using the seaborn library [56]. 
The same protocol was repeated for the 500 ns simula-
tions for compounds 1, 5, CGS21680, and the  A2AR pro-
tein crystal structures (PDB IDs: 2YDO and 5UI4) (each 
performed in duplicate).
Materials
Triazoloquinazolines 1–6 were supplied from Ambinter 
(Orléans, France), and CGS21680, NECA and ZM241385 
from Tocris Biosciences (Abingdon, UK) (%purity ≥ 95). 
All compounds were stored in 10 mM stock solutions in 
DMSO. Rolipram was purchased from Cayman chemi-
cals (Michigan USA), and other laboratory reagents were 
from Sigma-Aldrich (Poole, UK), of analytical grade.
Mammalian cell culture
CHO-K1 (gifted by Dr. Ewan St. John Smith, University 
of Cambridge, UK) CHO-K1-A2AR and CHO-K1-A3R 
cells (gifted by Prof. Karl-Norbert Klotz, University of 
Wuerzburg, Germany), were routinely cultured in Hams 
F-12 nutrient mix, supplemented with 10 % fetal bovine 
serum (FBS). H520, H1563, H1792 and LK-2 cells (gifted 
by Dr. Whalid Khaled, University of Cambridge, UK) 
were grown in RPMI media + 10 % FBS. All media was 
further supplemented with 1X antibiotic, antimycotic 
solution (Sigma Aldrich, Poole, UK). Culturing of all cell 
types was done at 37 °C in a humidified atmosphere con-
taining 5 %  CO2.
Generation of CHO‑K1 cell line stably expressing the  A2AR
CHO-K1 cells stably expressing the  A2AR cells were 
generated via transfection with 500 ng pcDNA3.1-A2AR 
(cDNA.org), per well of a 24-well plate, which was per-
formed with FuGENE HD (Promega, Wisconsin, USA), 
at a 1:3 (w/v) DNA:FuGENE ratio. Prior to adding 
800 µg/ml G418 (Sigma Aldrich, Poole, UK), the cells 
were further cultured for 48 hours. Then every 48 hours, 
G418 containing media were replaced until foci of cells 
were attained, which were left to grow to 100 % conflu-
ency. Afterwards, each well was tested for the ability of 
CGS21680 to elevate cAMP, performing further cultur-
ing with appropriately responding clones as described.
Phosphodiesterase 10A inhibition assays
A PDE10A assay kit (BPS Bioscience, San Diego, CA) 
was used to test the PDE10A inhibition of compounds 
1–6 as described in the manufactures protocol. 400 pg of 
purified PDE10A was used per reaction, and the plates 
were read using a TECAN infinite M200.
Yeast methods
Generation of yeast strains was done according to previ-
ously reported protocols, and they have been routinely 
grown as previously described [45]. Yeast cells expressing 
either the  A1R,  A2AR, or  A2BR were treated with either 
NECA, CGS21680 or compounds 1–6, in order to meas-
ure the activity of each, as previously described [45].
Bioluminescence Resonance Energy transfer (BRET)‑based 
ligand binding of triazoloquinazolines
HEK293T cells were seeded in 6-well plates at density of 
 106 cells/well and grown overnight at  37oC in DMEM/
F12 medium supplemented with 10 % FBS and 1 % antibi-
otic/antimycotic. Cells were then transfected with 1.5 µg 
Nluc-A2AR construct (a gift from Dr. Stephen Briddon, 
and Professor Steven Hill, University of Nottingham, UK) 
per well using PEI method. The ratio of DNA:PEI used 
for this transfection was 1:6  in 150 mM NaCl [57]. Cells 
were grown overnight, harvested and seeded at a density 
of 50,000 cells/well into PLL-coated white 96-well plates 
(Greiner, UK) in complete growth medium and cul-
tured for a further 24 h. On the day of the assay, culture 
medium was discarded and replaced by 80 µl BRET buffer 
which consist of PBS supplemented with 0.9 mM  CaCl2, 
0.5 mM  MgCl2, and 1 % BSA (w/v). The assay was started 
by adding 10 µl of furimazine, the substrate of Nluc (Pro-
mega, UK) (diluted in BRET buffer) to a final concentra-
tion of 0.4 µM and the plate was incubated in the dark at 
room temperature for 5 minutes.
For association-dissociation kinetic experiments, fol-
lowing furimazine incubation, 40 nM of CA200645 (pur-
chased from Hello Bio, Bristol, UK) was added and the 
plate was immediately read. After 19 minutes stimula-
tion, CGS21680 was injected to give a final concentration 
of 10 µM. Whereas for competition association assays, 
after incubation with furimazine, CA200645 (300 nM) 
in the presence of unlabelled ligand (in a range of 10 pM 
to 100 µM) were added simultaneously. BRET signal was 
recorded for either 50 minutes or 20 minutes, for kinetic 
experiments or competition assay as appropriate, on a 
Mithras LB940 plate reader allowing sequential integra-
tion of signal detected from fluorescent probe CA200645 
and Nluc. The BRET ratio corresponds to the ratio of 
light emission from acceptor (red fluorescent probe, 
long pass filter > 610 nm) over donor (Nluc 460 nm). 
Ligand-induced ΔBRET was used to construct the asso-
ciation-dissociation kinetic of the fluorescence probe and 
competition binding curve of unlabelled ligands.
Page 15 of 17Kalash et al. J Cheminform           (2021) 13:17  
To determine  KD value of CA200645, the signals from 
kinetic assay was fit into “association then dissociation” 
equation which was built in Prism 8.4. With the purpose 
of validating BRET-based competition assay, several ref-
erence compounds including CGS21680, NECA, and 
isoprenaline were also included. Binding affinities were 
calculated from competition assay by fitting data to non-
linear regression using “one-site, fit Ki” model built in 
Prism 8.4. The concentration and  KD values of ‘hot’ ligand 
were set to 300 nM and 65 nM, respectively.
cAMP accumulation assays
Prior to assay, harvesting of cells was performed with trypsin 
containing 0.05 % EDTA, they were then washed with 
PBS, and subsequently resuspended in stimulation buffer 
(PBS Proliferation assays containing 0.1 % BSA and 25 µM 
rolipram). Seeding of cells was done at 2000 cells  well− 1 
of a 384-well white optiplate, and then they were stimu-
lated at room temperature with compounds 1–6 (ranging 
100 pM-10 mM) for 30 minutes. The cells were subsequently 
lysed, and the measurement of cAMP levels was done using 
a LANCE cAMP detection kit (PerkinElmer), and the plates 
were read with a Mithras LB940 microplate reader.
Proliferation assays
To test the effect of compounds 1–6 upon proliferation, 
various cell types were seeded onto clear 96-well plates 
at proper densities for each; CHO-K1 (2000 cells  well− 1), 
CHO-K1-A2AR (2000 cells  well− 1), H520 (2500 cells  well− 1), 
H1563 (2500 cells  well− 1), H1792 (2500 cells  well− 1), LK-2 
(2500 cells  well− 1). This was done in suitable media, and 
they were cultured for 24 hours. After the subsequent addi-
tion of compounds 1–6 (ranging 316 nM − 100 µM), cells 
were allowed to grow further for 72 hours. Quantification 
of changes in cell number was done by adding 5 µl CCK-8 
reagent to each well, accompanied by incubation at 37 °C for 
1–3 hours. The determination of  OD450 was done using a 
Mithras LB940 micro-plate reader at 450 nm.
RT‑PCR
Extraction of RNA from H520, H1792, H1563 and LK-2 
cells was done using a RNAqueous®-4PCR Total RNA 
Isolation Kit (Life Technologies, Paisley, UK) as per the 
manufacturer’s instructions. Then, DNAse I treatment 
was performed to remove the contamination by genomic 
DNA. Subsequently, the quantification of the degree 
of purity of RNA samples was performed using a Nan-
oDrop™ Lite spectrophotometer (Thermo Scientific, 
UK). The samples that were used in cDNA synthesis are 
those of yields > 100 ng/µL and  A260/280 ratios > 1.9. The 
cDNA synthesis was done using a QuantiTect reverse 
transcription kit (Qiagen, Manchester, UK), for which 
a total of 1 µg of freshly isolated RNA was consumed 
per reaction. RT-PCR was subsequently implemented 
according to what has been previously reported[58]. The 
RT-PCR that has been done used gene specific primers 
to human: GAPDH (Sense 5’–TGC ACC ACC AAC TGC 
TTA GC– 3’; Antisense 5’-GGC ATG GAC TGT GGT CAT 
GAG–3’), A1R (Sense 5’-CCA CAG ACC TAC TTC CAC 
ACC–3’; Antisense 5’–TAC CGG AGA GGG ATC TTG 
ACC–3’, Primerbank ID − 115305570C1), A2AR (Sense 
5’-CGC TCC GGT ACA ATG GCT T–3’; Antisense 5’–
TTG TTC CAA CCT AGC ATG GGA–3’, Primerbank ID 
− 156142194C1), A2BR (Sense 5’–TGC ACT GAC TTC 
TAC GGC TG–3’; Antisense 5’–GGT CCC CGT GAC CAA 
ACT T–3’, Primerbank ID − 22907046C1), A3R (Sense 
5’–GGC CAA TGT TAC CTA CAT CACC–3’; Antisense 
5’–CCA GGG CTA GAG AGA CAA TGAA–3’, Primerbank 
ID − 4501953A1) and PDE10A (Sense 5’-TGA TGA CTT 
TTC TCT CGA CGT TG–3’; Antisense 5’–AAG CCA CCT 
ACA CAG TGT CTC–3’, Primerbank ID − 359465520C1). 
Then, gel electrophoresis (using 2 % agaorse gels) was 
performed to resolve PCR products. The imaging of gels 
was subsequently done using a G Box iChemi gel docu-
mentation system employing GeneTools analysis soft-
ware (Syngene, Cambridge, UK) and densitometry.
Data analysis
Data analysis was performed using GraphPad Prism 8.2.1 
(San Diegeo, CA). All data for β-galactosidase assays 
were normalized to the responses resulting from NECA 
stimulation, whereas the data for cAMP inhibition/accu-
mulation assays were normalised to those obtained upon 
stimulation with 100 µM Forskolin or CGS21680. As for 
proliferation assays, the normalization of all data was 
done relative to the responses obtained upon treating 
cells with 1 % (v/v) DMSO. Subsequently, a three-param-
eter logistic equation was used for fitting each set of nor-
malized data β-galactosidase or cAMP data, in order to 
calculate  pEC50/pIC50 and  Emax values. Also, the fitting 
of the proliferation data was done using a three-param-
eter logistic equation constraining the basal value to 100 
and the system maximum to the  IMax value obtained for 
compound 2, since it elicited the maximum inhibition of 
cellular proliferation in all cell types tested. A one-way 
ANOVA with Dunnett’s post-test, or Student’s t-test was 
used to assess the statistical significance for all assays, 
where p < 0.05 was considered to be significant.
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